S Korea Celltrion's candidate Covid-19 drug gets approval for special-case use
The Ministry of Food and Drug Safety approved CT-P59 under its patient treatment scheme on Friday, its website showed
Doctors can administer South Korean pharmaceutical maker Celltrion Inc's candidate Covid-19 antibody treatment to patients with life-threatening conditions, health authorities said on Tuesday.
The Ministry of Food and Drug Safety approved CT-P59 under its patient treatment scheme on Friday, its website showed.
Under the scheme, patients with life-threatening conditions and with no other means of treatment can receive drugs still undergoing clinical trials, the ministry said.
Keep updated, follow The Business Standard's Google news channel
Celltrion is conducting second- and third-phase clinical trials for CT-P59, and plans to seek emergency-use approval for the treatment before year-end, a company spokesman said.
The treatment is expected to be administered to the first patients "soon", Korea Disease Control and Prevention Agency official Kwon Jun-wook said in a briefing on Tuesday.
